** Shanghai Henlius Biotech 2696.HK soars 10.8% to HK$20.50; set for biggest one-day pct gain since June 25, 2024
** Stock hits highest since January 14; on course for fifth straight session of gains
** Biopharmaceuticals products maker grants India-based Dr. Reddy's Laboratories SA REDY.NS license to develop, manufacture and commercialise HLX15 in the U.S. and 42 European countries, including the UK and Switzerland, as it deepens overseas expansion
** Says Dr. Reddy's will pay $33 mln upfront and milestone payments of up to $98.6 mln in total and royalties of up to 8% of annual net sales
** HLX15 is used to treat multiple myeloma
** REDY up 0.1%; set for fourth straight session of gains
** Shanghai Henlius's stock soared 70.5% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。